We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Primary Screening Test for Diabetes Reevaluated

By LabMedica International staff writers
Posted on 04 Jan 2012
The blood test for glycosalated hemoglobin, Hb1Ac, has been recently recommended as the primary diagnostic test for diabetes. More...


The HbA1c blood test is the accepted standard for monitoring long-term glycemic control in patients with diabetes, however until recently, HbA1c was not recommended for diagnosing or screening for diabetes.

In a retrospective study carried out by DynaLIFEDx, Edmonton, AB, Canada) in conjunction with local medical practitioners, evaluated the positive predictive value (PPV) and negative predictive value (NPV) of HbA1c against the oral glucose tolerance test (OGTT) values using a 10% prevalence of diabetes in three locations. DynaLIFEDx is a major Canadian medical laboratory offering a complete range of diagnostic testing services. For a three-year period, 3,163 data pairs were collected including 1,537 males and 1,626 females with a mean age of 55.4 ± 14.7 years. The OGTT criteria for diabetes were found for 568 out of the 3,163 sets.

Blood glucose was measured on the ARCHITECT ci8200 (Abbott Laboratories; Mississauga, ON, Canada) using a hexokinase method and HbA1c was measured by high performance liquid chromatography (HPLC) on a VARIANT II analyzer (Bio-Rad laboratories, Montreal, QC, Canada). The recommended threshold HbA1c value of 6.5% did not give the optimal combination of NPV of 0.93 to 0.92 and PPV of 0.40 to 0.61 compared to a threshold HbA1c value of 7.0% that gave an NPV of 0.91 to 0.92, and PPV of 0.61 to 0.73.

The authors concluded that HbA1c is not satisfactory for use as a diagnostic test for diabetes using the threshold values recommended by the Consensus Committee and the International Expert panel due to low positive predictive values. About 12% of individuals with a normal OGTT test will be diagnosed with diabetes using a threshold HbA1c value of 7.0%. This would put considerable burden on health care resources. However, based on the high negative predictive value, HbA1c may be used as a test to rule-out diabetes. The study was published in the December 2011 issue of the journal Clinical Biochemistry.

Related Links:

DynaLIFEDx
Abbott Laboratories
Bio-Rad



New
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Food Allergy Screening ELISA Kit
Allerquant 14G B ELISA
New
Electrolyte Analyzer
CBS-4000 (CBS-400)
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Accurate immunotherapy selection for esophageal and GEJ carcinomas depends on consistent PD-L1 assessment (credit: Adobe Stock)

FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas

Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.